Literature DB >> 19818313

Non-alcoholic fatty liver disease: is bariatric surgery the answer?

Anjana A Pillai1, Mary E Rinella.   

Abstract

As the worldwide obesity epidemic continues to increase, the prevalence of non-alcoholic fatty liver disease (NAFLD) and specifically non-alcoholic steatohepatitis (NASH) will become increasingly prominent. NASH will surpass chronic hepatitis C infection as the primary indication for orthotopic liver transplantation in the near future. With the evolution of surgical techniques, bariatric surgery is currently recognized as the most effective method for achieving sustained weight loss and reversing numerous comorbidities in severely obese individuals. This review focuses on the potential risks and benefits of bariatric surgery in subjects with NAFLD and explores its role in the management of NASH in the obese patient.

Entities:  

Mesh:

Year:  2009        PMID: 19818313     DOI: 10.1016/j.cld.2009.07.012

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  18 in total

1.  Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients.

Authors:  Chi-Ming Tai; Chih-Kun Huang; Jau-Chung Hwang; Hung Chiang; Chi-Yang Chang; Ching-Tai Lee; Ming-Lung Yu; Jaw-Town Lin
Journal:  Obes Surg       Date:  2012-07       Impact factor: 4.129

Review 2.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 3.  Management of NAFLD: a stage-based approach.

Authors:  Mary E Rinella; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

4.  Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer.

Authors:  Jessica M Ellis; David S Paul; Michael A Depetrillo; Bhanu P Singh; David E Malarkey; Rosalind A Coleman
Journal:  Toxicol Pathol       Date:  2012-01-03       Impact factor: 1.902

5.  Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

Authors:  Thuy-Anh Le; Rohit Loomba
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

6.  Evolution of Liver Steatosis Quantified by MR Imaging and MR Spectroscopy, in Morbidly Obese Patients Undergoing Sleeve Gastrectomy: Short-Term Outcomes.

Authors:  María Engracia Alsina; Jaime Ruiz-Tovar; Angela Bernabeu
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

7.  The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

Authors:  Lisa B Van Wagner; Mary E Rinella
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

8.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 9.  Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease.

Authors:  Christine C Hsu; Erik Ness; Kris V Kowdley
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

Review 10.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.